

*Quarterly Statement  
first quarter 2020*

'20

---

*PUBLICATION DATE 14 MAY 2020*

## **HIGHLIGHTS**

- ▶ *SUCCESSFUL START INTO 2020 WITH STRONG STRATEGIC POSITION*
- ▶ *CONTINUED POSITIVE FINANCIAL PERFORMANCE; NO MATERIAL IMPACT THROUGH COVID-19 PANDEMIC SO FAR*
- ▶ *IMPORTANT STRATEGIC STEP INTO GENE THERAPY*
- ▶ *GUIDANCE FOR FULL-YEAR 2020 CONFIRMED*

### ***STRONG PERFORMANCE IN BASE BUSINESS; INCREASED REVENUES***

#### ***DESPITE MODEST MILESTONE CONTRIBUTIONS IN Q1***

- ▶ 15% increase in group revenues from contracts with customers to € 119.4 m (Q1 2019: € 103.8 m)
- ▶ Strong revenue growth in both segments: EVT Execute revenues up 18% to € 118.2 m (Q1 2019: € 100.3 m), EVT Innovate revenues up 24% to € 23.3 m (Q1 2019: € 18.8 m)
- ▶ Stable adjusted Group EBITDA of € 30.0 m (Q1 2019: € 30.0 m); adjusted EBITDA of € 35.4 m for EVT Execute (Q1 2019: € 32.2 m)
- ▶ Increased commitment into unpartnered R&D with expenses of € 11.4 m (Q1 2019: € 8.1 m)
- ▶ Continued strong strategic liquidity position of € 320.7 m (31 December 2019: € 320.0 m)
- ▶ No material impact by COVID-19 pandemic on financial development so far

### ***EVT EXECUTE & EVT INNOVATE – STRONG PERFORMANCE AND STRATEGIC POSITION IN BOTH BUSINESS SEGMENTS***

- ▶ Important step into gene therapy with Evotec GT and multi-year gene therapy research alliance with Takeda
- ▶ New and extended drug discovery and development agreements in EVT Execute (e.g. Amgen, Ildong)
- ▶ Just – Evotec Biologics on track for success: Strengthened position through first strategic J.POD® partnership with MSD and continued good construction progress of the first J.POD® facility in Seattle
- ▶ Advancement of an additional endometriosis programme into clinical Phase I within Bayer alliance, triggering a € 2m milestone payment
- ▶ Strengthening of Evotec's iPSC-based cell therapy platform EVOcells through licensing agreement with panCELLa
- ▶ Regaining global rights on iPSC-based beta cell replacement therapy from Sanofi and initiation of EVT Innovate initiative QRbeta Therapeutics (after period-end)
- ▶ Strategic equity investment and partnership with leon-nanodrugs expands formulation platform
- ▶ Evotec contributing to selected global initiatives to fight Tuberculosis and COVID-19

### ***GUIDANCE FOR FULL-YEAR 2020 CONFIRMED***

- ▶ Unchanged business outlook, taking into account currently visible negative COVID-19 effects
- ▶ Total group revenues expected to range from € 440 – 480 m (2019: € 446.4 m)
- ▶ Adjusted Group EBITDA expected to be in the range of € 100 – 120 m (2019: € 123.1 m)
- ▶ Unpartnered Group R&D expenses of approx. € 40 m

## **FINANCIAL HIGHLIGHTS**

The following table provides an initial overview of the financial performance in the first quarter of 2020 compared to the same period in 2019. More detailed

information can be found on page 5 of this quarterly statement.

### **Key figures of consolidated income statement & segment information**

*Evotec SE & subsidiaries – First quarter of 2020*

| <i>In T€</i>                           | <i>EVT<br/>Execute</i> | <i>EVT<br/>Innovate</i> | <i>Intersegment<br/>Eliminations</i> | <i>Not<br/>allocated<br/>(IFRS 15)<sup>4)</sup></i> | <i>Evotec<br/>Group<br/>Q1 2020</i> | <i>Evotec<br/>Group<br/>Q1 2019</i> |
|--|------------------------|-------------------------|--------------------------------------|---|-------------------------------------|-------------------------------------|
| External revenues <sup>1)</sup>        | 91,931                 | 23,333                  | –                                    | 4,138   | 119,402                             | 103,849                             |
| Intersegment revenues                  | 26,315                 | –                       | (26,315)                             | –   | –                                   | –                                   |
| <i>Gross margin in %</i>               | <i>29.3</i>            | <i>4.6</i>              | –                                    | –   | <i>27.9</i>                         | <i>30.5</i>                         |
| R&D expenses <sup>2)</sup>             | (1,310)                | (16,200)                | 2,454                                | –   | (15,056)                            | (14,359)                            |
| SG&A expenses                          | (14,053)               | (3,201)                 | –                                    | –   | (17,254)                            | (14,762)                            |
| Other operating income (expenses), net | 3,586                  | 11,547                  | –                                    | –   | 15,133                              | 16,526                              |
| <b>Operating result</b>                | <b>22,872</b>          | <b>(6,777)</b>          | –                                    | –   | <b>16,095</b>                       | <b>19,058</b>                       |
| <b>Adjusted EBITDA<sup>3)</sup></b>    | <b>35,413</b>          | <b>(5,411)</b>          | –                                    | –   | <b>30,002</b>                       | <b>30,036</b>                       |

<sup>1)</sup> Revenues in the segments consist of revenues from contracts with customers without revenues from recharges as those are not of importance for the management to assess the economic situation of the segments.

<sup>2)</sup> Thereof unpartnered R&D expenses of € 11.4 m in Q1 2020 (2019: € 8.1 m)

<sup>3)</sup> Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result; adjusted for positive exchange rate effects in the amount of € 0.9 m, EBITDA amounts to € 29.1 m

<sup>4)</sup> Not allocated to segments: Material charges according IFRS 15

### **So far, no material impact of COVID-19 pandemic on Evotec's business**

Within the first quarter of 2020, all sites at Evotec were able to continue operations. New health and safety rules have been introduced quickly and working processes adjusted to protect Evotec's employees and secure operations. Despite this difficult environment, which mainly started to affect Evotec during March, no significant financial impact is recognisable so far.

## **OPERATIONAL HIGHLIGHTS**

### **EVT EXECUTE**

#### **Important step into the gene therapy market**

In the first quarter 2020, Evotec established Evotec GT, a dedicated initiative for research and development of

gene therapy-based projects, centered in Orth/Donau, Austria and signed a long-term research alliance with Takeda. The alliance covers selected Takeda gene therapy projects for core therapeutic areas as oncology, rare diseases, neuroscience and gastroenterology.

#### **Multiple drug discovery and development alliances**

In the first quarter of 2020, the EVT Execute segment continued its strong progress. In the first three months of 2020, Evotec signed various new drug discovery and development agreements.

Evotec expanded its existing relationship with Amgen through a new agreement. The company will apply its integrated drug discovery and development platform to design and evaluate novel drug candidates for Amgen's proprietary development pipeline. The multi-year engagement aims to deliver small molecule pre-clinical

development (“PDC”) and investigational new drug (“IND”) ready candidates. The newly established engagement builds on an existing successful relationship between Evotec and Amgen.

Furthermore, Evotec and Ildong, a leading pharmaceutical company in South Korea, initiated a collaboration accessing Evotec’s INDiGO platform. The collaboration aims to accelerate the development of several of Ildong’s proprietary projects via access to Evotec’s integrated platform.

### ***Successful start for Just – Evotec Biologics***

Just – Evotec Biologics had a very good start to 2020. With the signing of a multi-year cooperation with its first J.POD® partner MSD (the tradename of Merck & Co., Inc.) and of a development and manufacturing agreement with multiple other parties, Just – Evotec Biologics strengthened its position. Furthermore, Just – Evotec Biologics started with the development of a library of a new class of humanoid antibodies using a novel, AI-derived approach. After period-end, Just Evotec Biologics entered into a partnership with Ology Bioservices Inc. for the evaluation and analytical characterisation of antibodies against SARS-CoV-2. This project falls under a grant awarded to Ology Bio and Vanderbilt University Medical Center by the US department of Defense to develop, and manufacture monoclonal antibodies for treatment and prevention of infections.

## ***EVT INNOVATE***

### ***Good pipeline progress***

Bayer AG continues to progress the pipeline around the P2X<sub>3</sub> molecule very effectively and has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development. As a result, Evotec received a milestone payment of € 2 m.

### ***Continued expansion of iPSC leadership***

In the first quarter Evotec signed a licensing and investment agreement with the biotech company

panCELLa. In the course of this collaboration, Evotec will expand its iPSC-based cell therapy platform EVOcells by getting access to panCELLa’s proprietary iPSC cell lines “iACT Stealth Cells™”, genetically modified cells preventing immune rejection of derived cell therapy products (“cloaking”).

After period-end, Evotec regained the global development and commercialisation rights of the iPSC-based programme for the treatment of diabetes from Sanofi. The beta cell programme has already achieved successful pre-clinical data demonstrating that they are functionally equivalent to primary human islets in their ability to normalise blood glucose levels in *in vivo* models over several months. Evotec will continue the development of the beta cell programme on its own within its EVT Innovate initiative “QRbeta Therapeutics”. In parallel, Evotec will explore the best strategic options for further long-term development and commercialisation.

### ***Stepping into nanotechnology***

Evotec entered into the field of nanotechnology by signing a strategic partnership with the Munich-based company leon-nanodrugs, the leading enabler of nanotechnology for the pharmaceutical industry. In the first quarter, Evotec in parallel made a strategic investment in leon by leading the company’s successful Series B funding round.

In the course of the cooperation, Evotec and leon will cooperate on selected development programmes and maximise the effectiveness of clinical and commercial medicines through nanotechnology.

### ***Evotec joining global collaboration against tuberculosis and COVID-19***

Evotec is member of the newly launched global collaboration to develop transformative treatment regimens for tuberculosis, called PAN-TB and is also member of ERA4TB, an international consortium to accelerate the development of comprehensive treatments against tuberculosis. Furthermore, Evotec is involved in selected activities in the global fight against COVID-19 (e.g. National Institute of Health).

## **REPORT ON THE FINANCIAL SITUATION AND RESULTS**

*Just-Evotec Biologics (JEB, former Just.Bio) was acquired effective July 2, 2019 and was fully consolidated in the group numbers from the respective date onwards. Hence, 2019 and 2020 numbers are not fully comparable for Q1.*

### **1. Results of operations**

Evotec's group revenues from contracts with customers for the first quarter of 2020 grew to € 119.4 m, a significant increase of 15% compared to the same period of the previous year (Q1 2019: € 103.8 m). This increase resulted primarily from a strong performance in the base business across all business lines, as well as the additional revenues from Just – Evotec Biologics (€ 7.9 m). Also, exchange rate effects had a positive impact of € 1.6 m on the group revenues. Evotec's base revenues for the first quarter 2020 were € 114.0 m (including impact from IFRS 15 of € 5.3 m), an increase of 22% over the same period of the previous year (Q1 2019: € 93.7 m). In total, revenues from milestones, upfront payments and licences decreased to € 5.4 m compared to last period (Q1 2019: € 10.1 m), including predominantly the milestone from Bayer. It has to be noted, that revenues from milestone payments can vary significantly from quarter to quarter.

**Costs of revenue** for the first quarter of 2020 amounted to € 86.1 m (Q1 2019: € 72.2 m) yielding a gross margin of 27.9% (Q1 2019: 30.5%). The margin in the first quarter 2019 was positively impacted by higher margin-rich milestone and upfront revenues compared to the first quarter 2020.

Total R&D expenses for the first quarter of 2020 increased as planned by nearly 5% to € 15.1 m (Q1 2019: € 14.4 m). Thereof, **unpartnered R&D expenses** increased to € 11.4 m (Q1 2019: € 8.1 m), mainly due to intensified research investments into oncology and platforms such as PanOmics and cell therapy.

**Partnered R&D expenses** amounted to € 3.7 m (Q1 2019: € 6.2 m), primarily related to its infectious disease portfolio. Whereas costs of the partnership with

Sanofi in this area are predominantly reported as R&D expenses the full reimbursement by Sanofi is recognised under other operating income.

**SG&A expenses** for the first quarter of 2020 increased by 17% to € 17.3 m (Q1 2019: € 14.8 m) and were mainly impacted by the consolidation of Just – Evotec Biologics, strategic measures and equity investments as well as personnel expenses due to an overall staff increase.

**Other operating income and expenses, net** in the first three months of 2020 amounted to € 15.1 m (Q1 2019: € 16.5 m) and was mainly influenced by reduced R&D tax credits at Verona site. Due to a change in the tax regulations in Italian legislation, a reduction in tax credits is expected. Accordingly, the **operating result** decreased to € 16.1 m (Q1 2019: € 19.1 m).

The **non-operating result** rose significantly to € 7.9 m year-on-year (Q1 2019: € (1.7 m)). Among other things, this was due to high foreign exchange gains of € 4.4 m (Q1 2019: € 0.4 m).

**Adjusted Group EBITDA** of the first three months of 2020 with € 30.0 m remained stable compared to the same period 2019 (Q1 2019: € 30.0 m) despite lower revenues from milestone payments, upfront and license contributions. In addition, favorable exchange rate developments had a positive effect of € 0.9 m on the Group EBITDA.

The **net result** in the first quarter of 2020 amounted to € 17.1 m (Q1 2019: € 13.1 m). The net result was positively affected by a favourable FX result and a gain from equity investments.

### **2. Operating segments EVT Execute and EVT Innovate**

Revenues from the EVT Execute segment amounted to € 118.2 m (incl. intersegment revenues) in the first quarter of 2020, an increase of 18% compared to the same period of the previous year (Q1 2019: € 100.3 m). This increase was primarily caused by a strong base business, including a contribution of € 7.9 m by

Just – Evotec Biologics. Intersegment revenues amounted to € 26.3 m (Q1 2019: € 18.7 m). The EVT Execute segment recorded costs of revenue of € 83.6 m in the first three months of 2020 (Q1 2019: € 71.2 m), resulting in a gross margin of 29.3%, which was nearly at the same level compared to the first quarter of 2019 with 29.0%. The R&D expenses in the EVT Execute segment amounted to € 1.3 m (Q1 2019: € 0.1 m), SG&A expenses were at € 14.1 m (Q1 2019: € 12.0 m). In the first three months of 2020, the adjusted EBITDA of the EVT Execute segment reached € 35.4, an increase of 10% compared to the previous year (Q1 2019: € 32.3 m).

The EVT Innovate segment generated revenues in the amount of € 23.3 m (Q1 2019: € 18.8 m), consisting entirely of third-party revenues. This increase of 24% in EVT Innovate revenues was mainly driven by additional revenues in infectious disease (partnership with Bill & Melinda Gates Foundation) and kidney disease (Vifor partnership – Joint Venture NephThera). The gross margin amounted to 4.6% compared to 24.8% in the prior-year period due to lack of comparable amount of milestone revenues in Q1 2020. R&D expenses for the EVT Innovate segment with € 16.2 m stayed stable in the first three months of 2020 (Q1 2019: € 16.3 m). SG&A expenses amounted to € 3.2 m (Q1 2019: € 2.8 m).

The EVT Innovate segment reported an adjusted EBITDA of € (5.4) m (Q1 2019: € (2.3) m).

### **3. Financing and financial position**

**Cash provided by operating activities** for the first three months of 2020 amounted to € 27.1 m (Q1 2019: € (13.1) m) and resulted mainly from receiving prepayments from the Bayer PCOS collaboration and the MSD J.POD® upfront payment. In addition, further milestone payments were received determining the positive cash inflow from operations whereas bonus payments were made this quarter.

**Cash used in investing activities** for the first quarter of 2020 amounted to € (13.5) m compared to

cash provided by investing activities of € 1.2 m in the same period of the previous year. In the first three months of 2020, the proceeds from the sale of current investments amounted to € 10.8 m. The purchase of investments in associated companies and other long-term investments in the first three months of 2020 amounted to € 4.9 m and included cash investments in leon-nanodrugs, panCELLa Inc., NephThera and Fibrocor. Capital expenditure in property plant and equipment increased to € 16.3 m (Q1 2019: € 8.4 m) due to € 7.9 m specific investments in the new J.POD® facility in Redmond.

**Cash used in financing activities** for the first quarter of 2020 amounted to € (3.6) m (Q1 2019: € 11.1 m).

**Liquidity**, which includes cash and cash equivalents (€ 285.4 m) and investments (€ 35.3 m) amounted to € 320.7 m at the end of March 2020 and was basically unchanged compared to total liquidity at the end of 2019 (31 December 2019: € 320.0 m).

### **4. Assets, liabilities and stockholders' equity**

#### **Assets**

In the first three months of 2020, total assets increased to € 1,183.6 m (31 December 2019: € 1,180.9 m).

Trade accounts receivables and accounts receivables from associated companies and other long-term investments decreased to € 74.6 m (31 December 2019: € 83.6 m).

The decrease in current tax receivables to € 16.2 m (31 December 2019: € 22.8 m) is primarily related to payments received in the first quarter for R&D tax credits.

Prepaid expenses and other current assets increased significantly to € 27.8 m (31 Dec 2019: € 19.3 m) due to issues that had to be paid at the beginning of the year for the entire year 2020, such as insurances.

Investments accounted for using the equity method and other long-term investments amounted to € 46.2 m

(31 December 2019: € 41.2 m) and increased due to new cash investments in different companies and a fair value adjustment for the new Joint Venture NephThera which was partly offset by the share of the result of associates accounted for using the equity method.

#### **Liabilities**

Trade accounts payable increased to € 41.8 m (31 December 2019: € 31.3 m), mainly due to specific investments in the new J.POD® facility. Non-current lease obligations decreased to € 113.4 m (31 December 2019: € 117.5 m), mainly due to the regular repayments.

#### **Stockholders' equity**

As of 31 March 2020, Evotec's capital structure remained largely unchanged compared to the end of 2019. Due to the exercise of stock options and Share Performance Awards, there were in total 151,242,427 shares issued and outstanding with a nominal value of € 1.00 per share as of 31 March 2020.

Evotec's equity ratio as of 31 March 2020 slightly increased to 41.4% (31 December 2019: 40.5%).

## **FINANCIAL OUTLOOK**

### ***Guidance for full-year 2020 confirmed***

In the first three months 2020, the business environment worldwide was affected by the outbreak of the COVID-19 pandemic and is forecasted to be even more impacted in the following quarters. Evotec's business also has felt the effects of the crisis, but so far not as materially as other sectors. Within the reporting period no significant negative impact on Evotec's business was recorded in context of the COVID-19 pandemic.

## **5. Human Resources**

### **Employees**

At the end of March 2020, 3,145 people were employed within the Evotec Group (31 December 2019: 3,030 employees).

However, further potential effects of the crisis in the coming months are difficult to predict due to risks and uncertainties which are beyond Evotec's control. At present, the management of Evotec confirms the financial guidance published in the 2019 Annual Report on 26 March 2020.

|  | <b>Guidance 2020</b>        | <b>31 December 2019</b> |
|--|-----------------------------|-------------------------|
| Group revenues from contracts with customers | € 440 - 480 m <sup>2)</sup> | € 446.4 m               |
| Unpartnered R&D expenses                     | Approx. € 40 m              | € 37.5 m                |
| Adjusted Group EBITDA <sup>1)</sup>          | € 100 - 120 m <sup>2)</sup> | € 123.1 m               |

<sup>1)</sup> EBITDA is defined as earnings before interest, taxes, depreciation, and amortisation of intangibles. Adjusted EBITDA excludes contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result

<sup>2)</sup> Despite the loss of € 20 m subsidy payments from Sanofi and significantly ramping up J.POD® capacities

**Evotec SE and Subsidiaries**  
**Consolidated interim statement of financial position as of 31 March 2020**

| <i>in T€ except share data</i>  | <i>as of</i><br><b>31 March 2020</b> | <i>as of</i><br><b>31 December 2019</b> |
|---|--------------------------------------|---|
| <b>ASSETS</b>   |                                      |   |
| <b>Current assets:</b>  |                                      |   |
| – Cash and cash equivalents   | 285,410                              | 277,034                                 |
| – Investments   | 35,250                               | 42,988                                  |
| – Trade accounts receivables  | 68,244                               | 82,251                                  |
| – Accounts receivables from associated companies and other long-term investments    | 6,373                                | 1,365                                   |
| – Inventories   | 10,860                               | 10,749                                  |
| – Current tax receivables   | 16,155                               | 22,777                                  |
| – Contract assets   | 13,858                               | 11,451                                  |
| – Other current financial assets  | 611                                  | 1,640                                   |
| – Prepaid expenses and other current assets   | 27,862                               | 19,275                                  |
| <b>Total current assets</b>   | <b>464,623</b>                       | <b>469,530</b>                          |
| <b>Non-current assets:</b>  |                                      |   |
| – Investments accounted for using the equity method and other long-term investments | 46,150                               | 41,229                                  |
| – Property, plant and equipment   | 245,698                              | 239,229                                 |
| – Intangible assets, excluding goodwill   | 113,228                              | 116,994                                 |
| – Goodwill  | 252,916                              | 255,919                                 |
| – Deferred tax asset  | 33,182                               | 34,330                                  |
| – Non-current tax receivables   | 26,841                               | 22,718                                  |
| – Other non-current financial assets  | 23                                   | 23                                      |
| – Other non-current assets  | 905                                  | 940                                     |
| <b>Total non-current assets</b>   | <b>718,943</b>                       | <b>711,382</b>                          |
| <b>Total assets</b>   | <b>1,183,566</b>                     | <b>1,180,912</b>                        |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>   |                                      |   |
| <b>Current liabilities:</b>   |                                      |   |
| – Current loan liabilities  | 6,423                                | 6,343                                   |
| – Current portion of lease obligations  | 15,156                               | 14,388                                  |
| – Trade accounts payable  | 41,792                               | 31,319                                  |
| – Provisions  | 25,454                               | 33,150                                  |
| – Contract liabilities  | 80,022                               | 71,067                                  |
| – Deferred income   | 4,082                                | 2,338                                   |
| – Current income tax payables   | 1,795                                | 7,305                                   |
| – Other current financial liabilities   | 459                                  | 190                                     |
| – Other current liabilities   | 9,855                                | 12,855                                  |
| <b>Total current liabilities</b>  | <b>185,038</b>                       | <b>178,955</b>                          |
| <b>Non-current liabilities:</b>   |                                      |   |
| – Non-current loan liabilities  | 324,442                              | 324,886                                 |
| – Long-term lease obligations   | 113,383                              | 117,482                                 |
| – Deferred tax liabilities  | 20,836                               | 21,199                                  |
| – Provisions  | 22,382                               | 22,538                                  |
| – Contract liabilities  | 23,235                               | 33,785                                  |
| – Deferred income   | 4,770                                | 5,038                                   |
| – Other non-current financial liabilities   | 8                                    | -                                       |
| <b>Total non-current liabilities</b>  | <b>509,056</b>                       | <b>524,928</b>                          |
| <b>Stockholders' equity:</b>  |                                      |   |
| – Share capital   | 151,242                              | 150,903                                 |
| – Additional paid-in capital  | 788,144                              | 786,865                                 |
| – Accumulated other comprehensive income  | (20,716)                             | (19,562)                                |
| – Accumulated deficit   | (429,198)                            | (441,177)                               |
| <b>Equity attributable to shareholders of Evotec SE</b>                             | <b>489,472</b>                       | <b>477,029</b>                          |
| Non-controlling interest  | -                                    | -                                       |
| <b>Total stockholders' equity</b>   | <b>489,472</b>                       | <b>477,029</b>                          |
| <b>Total liabilities and stockholders' equity</b>                                   | <b>1,183,566</b>                     | <b>1,180,912</b>                        |



**Evotec SE and Subsidiaries**  
**Consolidated interim income statement for the period from 01 January to 31 March 2020**

| <i>in T€ except share and per share data</i>                              | <b>Three months ended<br/>31 March 2020</b> | <b>Three months ended<br/>31 March 2019</b> |
|---|---|---|
| Revenues from contracts with customers                                    | 119,402                                     | 103,849                                     |
| Costs of revenue  | (86,130)                                    | (72,196)                                    |
| <b>Gross profit</b>   | <b>33,272</b>                               | <b>31,653</b>                               |
| <b>Operating income and (expenses)</b>                                    |   |   |
| – Research and development expenses                                       | (15,056)                                    | (14,359)                                    |
| – Selling, general and administrative expenses                            | (17,254)                                    | (14,762)                                    |
| – Other operating income  | 16,943                                      | 18,398                                      |
| – Other operating expenses  | (1,810)                                     | (1,872)                                     |
| <b>Total operating expenses</b>   | <b>(17,177)</b>                             | <b>(12,595)</b>                             |
| <b>Operating income (loss)</b>  | <b>16,095</b>                               | <b>19,058</b>                               |
| <b>Non-operating income (expense)</b>                                     |   |   |
| – Interest income   | 1,085                                       | 191   |
| – Interest expense  | (2,750)                                     | (1,061)                                     |
| – Share of the result of associates accounted for using the equity method | 17  | (1,364)                                     |
| – Other income from financial assets                                      | 18  | 1   |
| – Foreign currency exchange gain (loss), net                              | 4,413                                       | 434   |
| – Other non-operating income (expense) net                                | (8)   | 106   |
| <b>Total non-operating income (expense)</b>                               | <b>2,775</b>                                | <b>(1,693)</b>                              |
| <b>Income before taxes</b>  | <b>18,870</b>                               | <b>17,365</b>                               |
| – Current tax expense   | (2,266)                                     | (2,523)                                     |
| – Deferred tax income   | 472   | (1,792)                                     |
| <b>Total taxes</b>  | <b>(1,794)</b>                              | <b>(4,315)</b>                              |
| <b>Net income</b>   | <b>17,076</b>                               | <b>13,050</b>                               |
| <b>thereof attributable to:</b>   |   |   |
| Shareholders of Evotec SE   | 22,226                                      | 13,055                                      |
| Non-controlling interest  | -   | (5)   |
| <b>Weighted average shares outstanding</b>                                | <b>150,951,064</b>                          | <b>149,140,885</b>                          |
| <b>Net income per share (basic)</b>                                       | <b>0.11</b>                                 | <b>0.09</b>                                 |
| <b>Net income per share (diluted)</b>                                     | <b>0.11</b>                                 | <b>0.09</b>                                 |

**Evotec SE**
**Evotec SE and Subsidiaries**
**Condensed consolidated interim statement of cash flows for the three months ended 31 March 2020**

| <i>in T€</i>   | <i>Three months<br/>ended<br/>31 March 2020</i> | <i>Three months<br/>ended<br/>31 March 2019</i> |
|--|---|---|
| <b>Cash flows from operating activities:</b>                                       |   |   |
| – Net income   | 17,076  | 13,050  |
| – Adjustments to reconcile net income to net cash provided by operating activities | 15,041  | 15,260  |
| – Change in assets and liabilities   | (4,985)   | (41,451)  |
| <b>Net cash provided by (used in) operating activities</b>                         | <b>27,132</b>                                   | <b>(13,141)</b>                                 |
| <b>Cash flows from investing activities:</b>                                       |   |   |
| – Purchase of current investments  | (3,042)   | -   |
| – Purchase of investments in associated companies and other long-term investments  | (4,904)   | (979)   |
| – Purchase of property, plant and equipment  | (16,341)  | (8,403)   |
| – Proceeds from sale of current investments  | 10,779  | 10,533  |
| <b>Net cash used in investing activities</b>                                       | <b>(13,508)</b>                                 | <b>1,151</b>                                    |
| <b>Cash flows from financing activities:</b>                                       |   |   |
| – Proceeds from option exercise  | 326   | 676   |
| – Proceeds from loans  | 41  | 28,399  |
| – Repayment lease obligation   | (3,564)   | (2,492)   |
| – Repayment of loans   | (405)   | (15,455)  |
| <b>Net cash provided by (used in) financing activities</b>                         | <b>(3,602)</b>                                  | <b>11,128</b>                                   |
| <b>Net decrease in cash and cash equivalents</b>                                   | <b>10,022</b>                                   | <b>(862)</b>                                    |
| – Exchange rate difference   | (1,646)   | 3,437   |
| – Cash and cash equivalents at beginning of year                                   | 277,034   | 109,055   |
| <b>Cash and cash equivalents at end of the period</b>                              | <b>285,410</b>                                  | <b>111,630</b>                                  |